Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean We...
What are the potential risks (regulatory, safety, reimbursement) that could offset the upside from the reported weight‑loss efficacy?
What are the timelines and probability of moving to Phase 3, and how does that compare to other obesity‑treatment pipelines?
How will the positive Phase 2 results affect VKN's short‑term price movement and trading volume?
4 days ago